Companies covered: Autolus Therapeutics PLC (NASDAQ:AUTL), Chinook Therapeutics Inc. (NASDAQ:KDNY), Gilead Sciences, Inc. (NASDAQ:GILD), Novartis AG (NYSE:NVS), Bristol-Myers Squibb Company (NYSE:BMY), Incyte Corporation (NASDAQ:INCY), Zoetis Inc. (NYSE:ZTS), IDEXX Laboratories, Inc. (NASDAQ:IDXX), Covetrus (NASDAQ:CVET), Henry Schein, Inc. (NASDAQ:HSIC), Chewy (NYSE:CHWY), Amazon.com, Inc. (NASDAQ:AMZN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Bausch Health Companies (NYSE:BHC), AbbVie Inc. (NYSE:ABBV), Moderna (NASDAQ:MRNA), BioNTech SE (ADR) (NASDAQ:BNTX), Biogen Inc. (NASDAQ:BIIB), UCB Unsponsored Belgium ADR (OTCMKTS:UCBJY), Landos Biopharma Inc. (NASDAQ:LABP), CohBar Inc. (NASDAQ:CWBR), Omeros Corporation (NASDAQ:OMER), STERIS Corporation (NYSE:STE), Cutera, Inc. (NASDAQ:CUTR), Establishment Labs Holdings Inc. (NASDAQ:ESTA), Glaukos Corp (NYSE:GKOS), Cooper Companies, Inc. (The) (NYSE:COO), SmileDirectClub (NASDAQ:SDC), Vericel Corporation (NASDAQ:VCEL), Baxter International Inc. (NYSE:BAX), Hill-Rom Holdings Inc (NYSE:HRC), Soliton Inc. (NASDAQ:SOLY), EssilorLuxottica SA (OTCMKTS:ESLOF), Pulse BioSciences Inc. (NASDAQ:PLSE), Passage Bio Inc. (NASDAQ:PASG), Taysha Gene Therapies Inc. (NASDAQ:TSHA), Iovance Biotherapeutics Inc. (NASDAQ:IOVA), Homology Medicines Inc. (NASDAQ:FIXX), Regenxbio Inc. (NASDAQ:RGNX), Tenaya Therapeutics Inc. (NASDAQ:TNYA), Astellas Pharma Inc. (OTCMKTS:ALPMF), LogicBio Therapeutics Inc. (NASDAQ:LOGC), Intellia Therapeutics Inc. (NASDAQ:NTLA), Pfizer, Inc. (NYSE:PFE), Allogene Therapeutics (NASDAQ:ALLO), Cellectis S.A. (NASDAQ:CLLS), CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), Rocket Pharmaceuticals (NASDAQ:RCKT), Krystal Biotech (NASDAQ:KRYS), uniQure N.V. (NASDAQ:QURE), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), GBS Inc. (NASDAQ:GBS), Inhibikase Therapeutics, Inc. (NASDAQ:IKT), Mesoblast Limited (NASDAQ:MESO), USA Equities Corp. (OTCMKTS:USAQ)
